USF2 Antibody

Knockout: USF2 Antibody [NBP1-92649] -

Knockout: USF2 Antibody [NBP1-92649] - USF2 depletion in MLLr leukemia cells. Q-PCR was performed to validate the transcriptional regulation of HOXA9 upon USF2 targeting by two sgRNAs (sgUSF2#2 and sgUSF2#3) in OCI-AML2 cells. Immunoblotting confirmed the complete depletion of USF2. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/33001025/) licensed under a CC-BY license.

Western Blot: USF2 Antibody [NBP1-92649] -

Western Blot: USF2 Antibody [NBP1-92649] - USF2 depletion in non-MLLr leukemia cells.(A) Q-PCR was performed to validate the transcriptional impact of HOXA9 upon USF2 targeting by two sgRNAs (sgUSF2#2 & sgUSF2#3) in OCI-AML3 cells. Immunoblotting confirmed the complete depletion of USF2. (B) Immunoblotting confirmed the complete depletion of USF2 in OCI-AML3 cells upon USF2 targeting by a sgRNA. (C) Q-PCR was performed to validate the transcriptional impact of HOXA9 upon USF2 targeting by two sgRNAs (sgUSF2#2 & sgUSF2#3) in U937 cells. Immunoblotting confirmed the complete depletion of USF2. (D) Immunoblotting confirmed the complete depletion of USF2 in U937 cells upon USF2 targeting by a sgRNA. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/33001025), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: USF2 Antibody [NBP1-92649] -

Western Blot: USF2 Antibody [NBP1-92649] - USF2 depletion in non-MLLr leukemia cells.(A) Q-PCR was performed to validate the transcriptional impact of HOXA9 upon USF2 targeting by two sgRNAs (sgUSF2#2 & sgUSF2#3) in OCI-AML3 cells. Immunoblotting confirmed the complete depletion of USF2. (B) Immunoblotting confirmed the complete depletion of USF2 in OCI-AML3 cells upon USF2 targeting by a sgRNA. (C) Q-PCR was performed to validate the transcriptional impact of HOXA9 upon USF2 targeting by two sgRNAs (sgUSF2#2 & sgUSF2#3) in U937 cells. Immunoblotting confirmed the complete depletion of USF2. (D) Immunoblotting confirmed the complete depletion of USF2 in U937 cells upon USF2 targeting by a sgRNA. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/33001025), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: USF2 Antibody [NBP1-92649] -

Western Blot: USF2 Antibody [NBP1-92649] - USF2 depletion in MLLr leukemia cells.(A) Flow cytometry analysis was performed on the HOXA9P2A-mCherry SEM cells targeted with lentiviral Cas9 & sgRNAs against USF1, USF2, & USF1/2 (DKO). (B) Q-PCR was performed to validate the transcriptional regulation of HOXA9 upon USF2 targeting by two sgRNAs (sgUSF2#2 & sgUSF2#3) in OCI-AML2 cells. Immunoblotting confirmed the complete depletion of USF2. (C) Q-PCR was performed to validate the transcriptional regulation of HOXA9 upon USF2 targeting by two sgRNAs (sgUSF2#2 & sgUSF2#3) in NOMO-1 cells. Immunoblotting confirmed the complete depletion of USF2. (D) Immunoblotting confirmed the complete depletion of USF1 in SEM cells upon USF1 targeting by a sgRNA. (E) Immunoblotting confirmed the complete depletion of USF1 in OCI-AML2 cells upon USF1 targeting by a sgRNA. (F) Immunoblotting confirmed the complete depletion of USF2 in MOLM13 cells USF2 targeting by two sgRNAs (sgUSF2#2 & sgUSF2#3). (G) Competitive proliferation assay was conducted by infecting MOLM13Cas9 cells with Lentiviral-mCherry-sgRNAs against luciferase (sgLuc) & USF2 (sgUSF2#2, 2#3 & 2#5) at about 50% efficiency. The mCherry% was quantified at days 0, 3, 7, 11, 15, 19, & 23 by flow cytometry to evaluate the growth disadvantage. A guide RNA targeting the survival essential gene RPS19 was included as a positive control for Cas9 activity. Guide RNAs targeting Luciferase gene (sgLuc) & the human ROSA26 gene (sgROSA26) were included as negative controls. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/33001025), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: USF2 Antibody [NBP1-92649] -

Western Blot: USF2 Antibody [NBP1-92649] - USF2 is required to maintain HOXA9 expression in MLLr leukemia.(A) Flow cytometry analysis was performed at day 8 on the HOXA9P2A-mCherry cells targeted with lentiviral Cas9 & four sgRNAs against USF2. The sgENL-targeted cells were used as positive controls while sgLuc targeted cells were used as negative controls. (B) Q-PCR analysis was conducted on the USF2-targeted cells to monitor the reduction of HOXA9. The sgENL targeted cells were used as positive controls while sgLuc-targeted cells were used as negative controls. Data shown are means ± SEM from three independent experiments. *p<0.05, **p<0.01, ***p<0.001, two-tailed Student’s t test. (C) Immunoblotting of USF2 in USF2 sgRNAs targeted cells. '*' denoted non-specific bands. (D) USF2 occupancy changes in sgLuc & sgUSF2-targeted SEM cells were characterized in HOXA9 locus (A1, HOXA1; AS3, HOXA-AS3; A7, HOXA7; A9, HOXA9).Time-course knock-down of USF2 & consequent HOXA9 expression analysis.Flow cytometry analysis was performed at day 0, 4, 6, 8, & 11 on the HOXA9P2A-mCherry cells targeted with lentiviral Cas9 & four sgRNAs against USF2. The sgLuc- & sgRosa26-targeted cells were included as negative controls. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/33001025), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: USF2 Antibody [NBP1-92649] -

Western Blot: USF2 Antibody [NBP1-92649] - USF2 depletion in MLLr leukemia cells.(A) Flow cytometry analysis was performed on the HOXA9P2A-mCherry SEM cells targeted with lentiviral Cas9 & sgRNAs against USF1, USF2, & USF1/2 (DKO). (B) Q-PCR was performed to validate the transcriptional regulation of HOXA9 upon USF2 targeting by two sgRNAs (sgUSF2#2 & sgUSF2#3) in OCI-AML2 cells. Immunoblotting confirmed the complete depletion of USF2. (C) Q-PCR was performed to validate the transcriptional regulation of HOXA9 upon USF2 targeting by two sgRNAs (sgUSF2#2 & sgUSF2#3) in NOMO-1 cells. Immunoblotting confirmed the complete depletion of USF2. (D) Immunoblotting confirmed the complete depletion of USF1 in SEM cells upon USF1 targeting by a sgRNA. (E) Immunoblotting confirmed the complete depletion of USF1 in OCI-AML2 cells upon USF1 targeting by a sgRNA. (F) Immunoblotting confirmed the complete depletion of USF2 in MOLM13 cells USF2 targeting by two sgRNAs (sgUSF2#2 & sgUSF2#3). (G) Competitive proliferation assay was conducted by infecting MOLM13Cas9 cells with Lentiviral-mCherry-sgRNAs against luciferase (sgLuc) & USF2 (sgUSF2#2, 2#3 & 2#5) at about 50% efficiency. The mCherry% was quantified at days 0, 3, 7, 11, 15, 19, & 23 by flow cytometry to evaluate the growth disadvantage. A guide RNA targeting the survival essential gene RPS19 was included as a positive control for Cas9 activity. Guide RNAs targeting Luciferase gene (sgLuc) & the human ROSA26 gene (sgROSA26) were included as negative controls. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/33001025), licensed under a CC-BY license. Not internally tested by Novus Biologicals.